Search results with tag "Gilead sciences"
HIGHLIGHTS OF PRESCRIBING INFORMATION ... - Gilead …
www.gilead.comThe most common adverse reactions (incidence greater than or equal to 5%, all grades) observed with treatment with VEKLURY are nausea, ALT increased, and AST increased. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or
ViiV 社の抗 HIV薬Dolutegravir に対する Gilead 社Biktarvy の …
www.shionogi.com1. GSK 社プレスリリース：2022 年2 月1 日 GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving litigation relating to Biktarvy and ViiV’s dolutegravir patents and entry into a patent licence agreement
Patient Information RANEXA (rah NEX ah) (ranolazine ...
www.gilead.comThe Patient Information summarizes the most important information about RANEXA. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about RANEXA that is written for health professionals. For more information, go to www.ranexa.com or call Gilead Sciences, Inc. at 1-800-445-3235.
PATIENT INFORMATION VEKLURY - Gilead Sciences
www.gilead.com1 PATIENT INFORMATION VEKLURY® (VEK-lur-ee) ® (remdesivir) for injection VEKLURY (VEK-lur-ee) (remdesivir) injection What is VEKLURY? VEKLURY is a prescription medicine used for the treatment of coronavirus disease 2019 (COVID-19) in adults and children 12 years of age and older and weighing at least 88 pounds (40 kg) who are ...
iShares Biotechnology ETF
www.ishares.comgilead sciences inc 7.13 moderna inc 5.82 regeneron pharmaceuticals inc 5.08 vertex pharmaceuticals inc 4.35 illumina inc 4.20 iqvia holdings inc 4.18 biontech se adr 3.13 mettler toledo inc 3.01 biogen inc 2.75 48.78 holdings are subject to change.
HIGHLIGHTS OF PRESCRIBING INFORMATION for DESCOVY. …
www.gilead.comsee 17 for patient counseling information and medication guide. revised: 01/2022 . gilead sciences 2 full prescribing information: contents* warning: post-treatment acute exacerbation of hepatitis b and risk of drug resistance with use of descovy for …
PRODUCT MONOGRAPH INCLUDING PATIENT …
www.gilead.caPRODUCT MONOGRAPH . INCLUDING PATIENT MEDICATION INFORMATION . PrVIREAD (tenofovir disoproxil fumarate) tablets . 300 mg . Antiretroviral Agent . Gilead Sciences, Inc.
AMENDED AND RESTATED LICENSE AGREEMENT …
www.gilead.comFinal Version 1 AMENDED AND RESTATED LICENSE AGREEMENT (TEMPLATE) This AMENDED AND RESTATED LICENSE AGREEMENT (the “Agreement”) is made as of July __, 2011 (the “Effective Date”) by and between Gilead Sciences, Inc. a
for BIKTARVY. BIKTARVY ...
www.gilead.comGilead Sciences 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BIKTARVY safely and effectively.
Similar queries
PRESCRIBING INFORMATION, Gilead, ADVERSE REACTIONS, Gilead Sciences, PATIENT INFORMATION, Information, 1 PATIENT INFORMATION, Counseling, PRODUCT MONOGRAPH INCLUDING PATIENT, PRODUCT MONOGRAPH . INCLUDING PATIENT MEDICATION INFORMATION, AMENDED AND RESTATED LICENSE AGREEMENT, AMENDED AND RESTATED LICENSE AGREEMENT TEMPLATE